| Product Code: ETC7349777 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Overview |
3.1 Greece Country Macro Economic Indicators |
3.2 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, 2021 & 2031F |
3.3 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market - Industry Life Cycle |
3.4 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market - Porter's Five Forces |
3.5 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume Share, By Brands, 2021 & 2031F |
4 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of diabetes in Greece |
4.2.2 Growing awareness about the benefits of GLP-1 agonists in managing diabetes |
4.2.3 Approval of new GLP-1 agonist drugs in the Greek market |
4.3 Market Restraints |
4.3.1 Pricing pressures and reimbursement challenges |
4.3.2 Competition from other diabetes management drugs |
4.3.3 Regulatory hurdles for introducing new medications |
5 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Trends |
6 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market, By Types |
6.1 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Dulaglutide, 2021- 2031F |
6.1.4 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Exenatide, 2021- 2031F |
6.1.5 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Liraglutide, 2021- 2031F |
6.1.6 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Lixisenatide, 2021- 2031F |
6.1.7 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Semaglutide, 2021- 2031F |
6.2 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market, By Brands |
6.2.1 Overview and Analysis |
6.2.2 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Byetta, 2021- 2031F |
6.2.3 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Bydureon, 2021- 2031F |
6.2.4 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Victoza, 2021- 2031F |
6.2.5 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Trulicity, 2021- 2031F |
6.2.6 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Lyxumia, 2021- 2031F |
6.2.7 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Ozempic, 2021- 2031F |
7 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Import-Export Trade Statistics |
7.1 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Export to Major Countries |
7.2 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Imports from Major Countries |
8 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Key Performance Indicators |
8.1 Patient adherence rate to GLP-1 agonist therapy |
8.2 Number of healthcare providers prescribing GLP-1 agonists |
8.3 Rate of new GLP-1 agonist drug approvals in Greece |
9 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market - Opportunity Assessment |
9.1 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Opportunity Assessment, By Brands, 2021 & 2031F |
10 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market - Competitive Landscape |
10.1 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Revenue Share, By Companies, 2024 |
10.2 Greece Glucagon like Peptide 1 (GLP 1) Agonists Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here